Christopher Kaufman
Venture Analyst @ Excell Partners
Rochester, United States
Christopher Kaufman is a startup investor at Excell Partners in Rochester. Christopher graduated with a B.S., magna cum laude, in Clinical Laboratory Science from Arizona State University and subsequently worked as a Medical Technologist at the Maricopa County Medical Center. He also holds a Ph.D. in Molecular, Cellular, Developmental Biology, and Genetics from the University of Minnesota where he studied thedevelopmental role of proto-oncogenes in vertebrate embryogenesis. Subsequent post-doctoral research focused on gene therapy optimization, during which he received a post-doctoral fellowship at the Max-Delbrück-Center for Molecular Medicine in Berlin, Germany and the NIH T32 training grant at the University of Rochester Medical Center. He has published multiple papers and traveled to international conferences to present his work. Christopher has also taught as an adjunct instructor in the Biology Department at Nazareth College. Christopher is currently pursuing a M.S. in Business Administration with a concentration in Medical Management at the University of Rochester’s Simon School of Business.
Last updated:
For AI agents: llms.txt
About Excell Partners
Excell is a New York State-supported seed fund. Although it is a not-for-profit organization, Excell maintains a for-profit discipline by structuring each investment with convertible debt and equity returns so that, over time, the fund becomes self-sustaining or evergreen.
Excell Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Christopher Kaufman
Venture Analyst
|
|||
|
James Watters
Director
|
|||
|
J. Montieth Estes
Director
|
|||
|
Maggie Brooks
Director
|
|||
|
Mary Ann Tyszko
Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
FAQ
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
